Navigation Links
Enzyme to Boost Effect of Tumor Vaccine

The effects of tumor vaccines seem to get boosted by a 'super' form of an enzyme called Akt1. This enzyme is expected //to help extend the life of dendritic cells. These cells are also referred to as the main switch of the immune system that improves the way the T-cells respond to attack a tumor. This was divulged in a report that appears in an electronic media, online in the latest issue of the journal Nature Biotechnology. Researchers from Baylor College of Medicine conducted the study.

The desirable immune response is achieved by maintaining the window of activation longer. This is possible by keeping dendritic cells alive for longer time explained Dr. David Spencer, associate professor of immunology at BCM. 'The longer your dendritic cells are alive and active, the more likely you are to expand the appropriate T-helper repertoire and ultimately the desirable cytotoxic (cell killing) T-lymphocytes.'

'The dendritic cells are the master switch in the immune system. They decide whether there will be a robust immune response or a tempered immune response to pathogens or cancer,' he said. Using a variety of sophisticated laboratory techniques, Spencer and his colleagues found that Akt1 'was in fact essential for dendritic cell survival,' he said. Then they sought to develop a more potent form of Akt1 that would enable the dendritic cells to live longer, boosting immune response.

To do that, they altered the enzyme so that it targeted a particular domain on the plasma membrane of the cell where signaling occurred, making the action of Akt1 more specific. They then eliminated a small part of the Akt1 molecule that had a negative or inhibitory effect. 'It turned out that the altered molecule was much more potent,' Spencer said. He credited graduate student Dongsu Park with doing much of the work to develop the super form of Akt1.

Using specially designed adenoviruses, he and his colleagues put the modified 'super' Akt1 molec ule into the dendritic cells. 'As predicted, these dendritic cells lived longer and were more potent, both in the laboratory and in mice,' he said. 'It led to the elimination of some very aggressive tumors in the mice.'

In the laboratory, they found that the 'super' Akt1 also has a potent effect on human dendritic cells as well, although it has not been used to treat people yet. He expects that when the enzyme is used in people, the first target will be prostate cancer – a long-standing interest of his laboratory. However, he said, it could be modified to attack other tumors as well.



Source-Eurekalert
MST
'"/>




Related medicine news :

1. Enzyme may be target for obesity drugs
2. Researchers trick Alzheimers Enzyme
3. Enzyme stimulates growth of adult stem cells
4. Enzyme may aid hold back disease
5. Enzyme help destroy cancer cell
6. Enzyme Associated with Memory
7. Enzyme Associated With Memory
8. Brain Enzyme Found To Regulate Weight
9. New Enzyme Identified For Arthritis
10. Enzyme for treatment of arthritis
11. An Enzyme That Turns a One –time Experience into a long-time Memor
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/26/2017)... , ... July 26, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is excited to announce the 106 college ... Ambassador Program. , Established in 2005, the Team Type 1 Foundation has bestowed ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
(Date:7/26/2017)... ... 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) ... development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned ... International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology: